Andrea Runow is New Acting Executive Board Member of the Berlin Institute of Health (BIH)

In her new role, Andrea Runow will be provisionally in charge of all business and administrative operations at BIH while, together with the other board members, also being responsible for management of the Institute. Professor Axel Radlach Pries, Dean of Charité – Universitätsmedizin Berlin and interim Chairman of the BIH Executive Board welcomes his new colleague on the Board: “In Andrea Runow we are gaining an experienced scientific manager for BIH, thus ensuring the stability and seamless operation of the Institute.” I look forward to working with her and am confident that together we can successfully develop BIH further.”

Andrea Runow is also looking forward to her new duties: “BIH’s mission of swiftly bringing research findings from the lab to patients is something that is very close to my heart. I’m pleased to be able to bring to bear my experience to this field.”

Runow studied economics at Humboldt-Universität zu Berlin, specializing in financial management. She began her career at the district administration of Riesa, where she held various financial management posts and eventually became head of the district administration, before moving to the Saxon State Ministry of Finance. In 1996, she joined the Leibniz Institute for Solid State and Materials Research Dresden (IFW), where she last served as Head of the Administration Department. Starting in 2007, she led the administrative operations of the Helmholtz-Zentrum Dresden-Rossendorf, which included the Departments of Personnel Affairs, Finance, Procurement, Central Services, and Administrative Information Technology. Andrea Runow is married and has two adult children.

About the Berlin Institute of Health (BIH)
The Berlin Institute of Health (BIH) is a biomedical research institution focusing on translational research and precision medicine. The BIH is dedicated to improving the prediction in progressive diseases and developing advanced therapies for unmet medical needs in order to improve patients’ health and quality of life. The Institute is committed to providing research solutions and innovation enabling value-based, personalized healthcare. The BIH is funded 90% by the Federal Ministry of Education and Research (BMBF) and 10% by the State of Berlin. The two founding institutions, Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), are independent, member entities within the BIH.

Saskia Blank
Science Communication Officer
+49 30 450 543044

Dr. Stefanie Seltmann
Head of Communication and Marketing
+49 (0)30 450 543 019

Scroll to Top